10x Genomics (NASDAQ:TXG) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Barclays Turns More Bullish on 10x Genomics, Inc. (TXG) Despite Uneven Research Spending [Yahoo! Finance]
10x Genomics (NASDAQ:TXG) had its price target raised by analysts at Canaccord Genuity Group Inc. from $19.00 to $20.00. They now have a "buy" rating on the stock.
10x Genomics (NASDAQ:TXG) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
10x Genomics (NASDAQ:TXG) was downgraded by analysts at Citigroup Inc. from a "buy" rating to a "cautious" rating.